

Report Price: £1995.00 | \$2583.33 | €2370.86

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.



"A need to keep going at work is helping to keep the value of the category afloat, but it is increasingly under threat from consumers trading down to generic painkillers."

- Lucy Cornford, Category Director - Personal Care

This report looks at the following areas:

- Nurofen fall-out continues to echo
- Promoting a holistic approach to pain management

A booming population combined with rising rates of employment have helped keep the category in growth as consumers look to keep on going, however bad they feel; a 2% rise in the value of the analgesics market in 2016 is expected to make way for a 4% rise in 2017, taking the market to £689 million

BUY THIS REPORT NOW

VISIT: store.mintel.com

CALL:EMEA
+44 (0) 20 7606 4533

Brazil 0800 095 9094

+1 (312) 943 5250

+86 (21) 6032 7300

APAC +61 (0) 2 8284 8100

EMAIL: reports@mintel.com

DID YOU KNOW?

This report is part of a series of reports, produced to provide you with a more holistic view of this market



Report Price: £1995.00 | \$2583.33 | €2370.86

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Table of Contents

Overview

What you need to know

Products covered in this Report

Excluded

Executive Summary

The market

Keep calm and carry on working

Figure 1: Best- and worst-case forecast of UK value sales of OTC analgesics, 2012-22

Companies and brands

Nurofen struggles with negative publicity

Figure 2: Brand shares in OTC analgesics, year to March 2017

Increased advertising spend and innovation benefit topical brands

Innovation returns to the category

Figure 3: New product launches in the OTC analgesics market, by launch type, January 2014-March 2017

The consumer

Oral remedies most sought

Figure 4: Actions taken to deal with pain, April 2017

Women most likely to use OTC analgesics

Figure 5: Usage of OTC analgesics in the last 12 months, April 2017

Men less prepared than women

Figure 6: How OTC analgesics were obtained when last experiencing pain, April 2017

Supermarkets lead buying locations

Figure 7: Locations for buying OTC analgesics in the last 12 months, April 2017

Consumers have low engagement with the category

Figure 8: Purchase factors for OTC analgesics, April 2017

Eating for better health

Figure 9: Actions taken to stay healthy in last 12 months, April 2017

What we think

Issues and Insights

Nurofen fall-out continues to echo

The facts

The implications

Promoting a holistic approach to pain management

The facts

The implications

The Market - What You Need to Know

BUY THIS REPORT NOW VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 | **EMAIL:** reports@mintel.com



Report Price: £1995.00 | \$2583.33 | €2370.86

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Workers boost category value

Topical analgesics drive growth

Supermarkets are popular buying locations

Exercise as a trigger and a remedy

NHS eyes prescription cuts

Trial by media

Market Size and Forecast

Keep calm and carry on working

Figure 10: UK retail value sales of OTC analgesics, at current and constant prices, 2012-22

Slow and steady growth to 2022

Figure 11: Best- and worst-case forecast of UK value sales of OTC analgesics, 2012-22

Forecast methodology

Market Segmentation

Topical remedies continue to drive growth

Figure 12: UK retail value sales of OTC analgesics, by segment, 2015-16

Channels to Market

Supermarkets remain popular buying locations

Figure 13: UK retail value sales of OTC analgesics, by outlet type, 2015-16

Topical analgesics boost sales through 'low cost' channels

Market Drivers

Benefits of an ageing population...

Figure 14: Trends in the age structure of the UK population, 2012-22

...could be outweighed by declining birth rate

Figure 15: Total fertility rate (TFR) and number of lives births, England and Wales, 2010-15

Employee sickness rates fall

Figure 16: Employment and unemployment, by gender, 2011-21

Dealing with stress

Figure 17: Factors causing stress, by gender, November 2016

Exercise as a trigger for pain...

Figure 18: Trial and interest in trying selected healthy living trends*, by age, August 2016

...and exercise as a remedy

Eating for better health

Figure 19: Reasons for eating healthily, November 2016

NHS eyes up prescription cuts

Painkillers in the media

Rising concerns over side-effects of oral analgesics

'Misleading' Nurofen claims spur negative publicity

Figure 20: Screenshot of Nurofen Joint & Back advert, 2016

BUY THIS REPORT NOW

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 | **EMAIL:** reports@mintel.com



Report Price: £1995.00 | \$2583.33 | €2370.86

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Online prescription risk could increase interest in OTC remedies

Companies and Brands - What You Need to Know

Nurofen struggles with negative publicity

Increased advertising spend and innovation benefit topical brands

Innovation returns to the category

Recorded advertising spend sees an uplift in 2016

Market Share

Nurofen value slips

Figure 21: Retail value sales of all OTC analgesics, by brand, years ending March, 2016 and 2017

Voltarol bounces back

Deep Heat benefits from roll-on launch

Launch Activity and Innovation

Innovation returns to the category

Figure 22: New product launches in the OTC analgesics market, by launch type, January 2014-March 2017

Figure 23: Examples of OTC analgesics launches with New Product or New Variety/Range Extension launch type, 2016

Own-label resurgence

Figure 24: New product launches in the OTC analgesics market, own-label vs branded, January 2014-March 2017

Figure 25: Examples of own-label launches in the UK OTC analgesics market, 2016

Tablet NPD increases

Figure 26: New product launches in the OTC analgesics market, by format type, January 2014-March 2017

Room for innovation in oral analgesics

Figure 27: Combogesic tablets (Thornton & Ross), 2016

Fighting the demon sugar

Figure 28: Top 10 fastest growing product positioning claims in the OTC analgesics market, 2015-16

Figure 29: Examples of new launches in the UK OTC analgesics market positioned for children, 2016

A fragmented market

Figure 30: New product launches in the OTC analgesics market, by top six ultimate companies and other, 2016

Advertising and Marketing Activity

2016 adspend surges

Figure 31: Total above-the-line, online display and direct mail advertising expenditure on OTC analgesics, January 2014-March 2017

Spend on outdoor advertising grows

Figure 32: Total above-the-line, online display and direct mail advertising expenditure on OTC analgesics, by media type, January 2014-March 2017

RB and GSK fight for top spot

Figure 33: Total above-the-line, online display and direct mail advertising expenditure on OTC analgesics, by top advertisers and other, January 2015-March 2017

Nielsen Ad Intel coverage

The Consumer - What You Need to Know

Oral remedies most sought

Pressure on NHS dentists provides opportunities for brands

BUY THIS REPORT NOW VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 | **EMAIL:** reports@mintel.com



Report Price: £1995.00 | \$2583.33 | €2370.86

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

The benefits of a holistic approach to back pain

Potential for analgesics brands to increase image of responsibility

Women most likely to use OTC analgesics

Presence of children could have an impact on product choice

Supermarkets lead buying locations

Consumers have low engagement with the category

Dealing with Head Pains

Oral remedies ease head pains

Figure 34: Actions taken to deal with head-related pains, April 2017

Dental pain sufferers seek out professional help

Dealing with Musculoskeletal and Period Pains

A mixed bag of treatments for musculoskeletal pain

Figure 35: Actions taken to deal with musculoskeletal pains, April 2017

Seniors prefer to keep moving

Preventing muscle pain in young adults

Menstrual/period pain

Figure 36: Actions taken to deal with period pain, by age, April 2017

Usage of OTC Analgesics

Women most likely to use analgesics

Figure 37: Usage of OTC analgesics in the last 12 months, by gender, April 2017

Paracetamol and ibuprofen most popular painkillers

Presence of children influences product choice

Buying OTC Analgesics

Men less prepared

Figure 38: How OTC analgesics were obtained when last experiencing pain, by gender, April 2017

Experience breeds preparedness

Buying ahead leads to more supermarket purchases

Figure 39: Locations for buying OTC analgesics in the last 12 months, April 2017

Low engagement with the category

Figure 40: Purchase factors for OTC analgesics, by gender, April 2017

Potential for more convenient liquid analgesics

Actions Taken to Stay Healthy

Healthy eating comes to the fore

Figure 41: Actions taken to stay healthy in last 12 months, April 2017

Health check-ups for younger adults

Figure 42: Selected actions taken to stay healthy in last 12 months, by age, April 2017

Appendix - Data Sources, Abbreviations and Supporting Information

BUY THIS REPORT NOW VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100

EMAIL: reports@mintel.com



Report Price: £1995.00 | \$2583.33 | €2370.86

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Abbreviations

Consumer research methodology

Forecast methodology

Appendix - The Market

Figure 43: Best- and worst-case forecast of UK value sales of OTC adult oral analgesics, 2012-22

Figure 44: Best- and worst-case forecast of UK value sales of OTC paediatric analgesics, 2012-22

Figure 45: Best- and worst-case forecast of UK value sales of OTC topical analgesics, 2012-22

Appendix - Companies and Brands

Figure 46: Retail value sales of OTC oral analgesics for adults (excluding oral lesion and toothache analgesics), by brand, years ending March, 2016 and 2017
Figure 47: Retail value sales of OTC paediatric analgesics, by brand, years ending March, 2016 and 2017

Figure 48: Retail value sales of OTC oral lesion and toothache analgesics, by brand, years ending March, 2016 and 2017

Figure 49: Retail value sales of OTC topical analgesics, by brand, years ending March, 2016 and 2017

APAC +61 (0) 2 8284 8100 **EMAIL:** reports@mintel.com